Dr. Michael Callahan was given a leave of absence from his senior executive role at United Therapeutics (UTHR) in the wake of the COVID-19 outbreak in Wuhan, China; sent there to assist colleagues handling mass infections of the novel coronavirus under his joint appointment at a Chinese sister hospital of the Massachusetts General Hospital/Harvard Medical School, where he has maintained a faculty appointment since 2005.
Soon, Callahan would be pouring through thousands of case studies emerging from the epicenter of the outbreak in Wuhan, examining patients in Singapore and briefing U.S. officials on the location of the next likely outbreak, according to NatGeo. The doctor marveled at the “magnificent infectivity” of the disease, which sits “like a little silent smart bomb in your community”.
The doctor’s strange fascination with viral infections and morbid titillation might well be attributed to the fact that he has dedicated his life to studying these microscopic killers. “Triple boarded” in internal medicine, infectious diseases and tropical medicine, Callahan, nevertheless also has a strong entrepreneurial streak, that drove him to launch no less than 11 companies and develop 8 patents.
Callahan’s nose for business came into play early on in the pandemic. Read more…